Brokerages expect that Bristol-Myers Squibb Co (NYSE:BMY) will post earnings of $0.87 per share for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Bristol-Myers Squibb’s earnings. The highest EPS estimate is $0.98 and the lowest is $0.74. Bristol-Myers Squibb posted earnings per share of $0.84 during the same quarter last year, which would suggest a positive year over year growth rate of 3.6%. The business is expected to announce its next earnings results on Thursday, April 26th.
According to Zacks, analysts expect that Bristol-Myers Squibb will report full year earnings of $3.27 per share for the current fiscal year, with EPS estimates ranging from $3.10 to $3.90. For the next year, analysts forecast that the company will post earnings of $3.94 per share, with EPS estimates ranging from $3.26 to $4.70. Zacks Investment Research’s EPS calculations are a mean average based on a survey of research firms that that provide coverage for Bristol-Myers Squibb.
Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.01. The company had revenue of $5.45 billion during the quarter, compared to the consensus estimate of $5.35 billion. Bristol-Myers Squibb had a return on equity of 35.43% and a net margin of 4.85%. The firm’s quarterly revenue was up 3.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.63 EPS.
BMY has been the subject of several research reports. BMO Capital Markets set a $49.00 price target on Bristol-Myers Squibb and gave the stock a “sell” rating in a research note on Thursday, October 26th. Piper Jaffray Companies reiterated a “hold” rating and set a $60.00 price target on shares of Bristol-Myers Squibb in a research note on Friday, October 27th. Credit Suisse Group reiterated a “hold” rating and set a $61.00 price target (up previously from $58.00) on shares of Bristol-Myers Squibb in a research note on Friday, October 27th. SunTrust Banks upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research note on Monday, October 30th. Finally, Zacks Investment Research upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $68.00 price target for the company in a research note on Wednesday, November 1st. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and eight have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $66.18.
Bristol-Myers Squibb (BMY) opened at $65.94 on Friday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.43 and a current ratio of 1.55. The firm has a market capitalization of $107,920.00, a price-to-earnings ratio of 27.94, a PEG ratio of 2.09 and a beta of 1.08. Bristol-Myers Squibb has a 12 month low of $51.56 and a 12 month high of $70.05.
The business also recently disclosed a quarterly dividend, which was paid on Thursday, February 1st. Investors of record on Friday, January 5th were issued a dividend of $0.40 per share. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend was Thursday, January 4th. This represents a $1.60 dividend on an annualized basis and a yield of 2.43%. Bristol-Myers Squibb’s dividend payout ratio is 67.80%.
In other Bristol-Myers Squibb news, EVP Thomas J. Jr. Lynch sold 5,300 shares of the firm’s stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $63.24, for a total value of $335,172.00. Following the sale, the executive vice president now owns 9,251 shares of the company’s stock, valued at approximately $585,033.24. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Theodore R. Samuels II purchased 4,000 shares of the stock in a transaction on Friday, December 15th. The stock was acquired at an average cost of $62.30 per share, for a total transaction of $249,200.00. Following the acquisition, the director now owns 22,000 shares in the company, valued at $1,370,600. The disclosure for this purchase can be found here. Corporate insiders own 0.23% of the company’s stock.
Several large investors have recently added to or reduced their stakes in the business. Blue Chip Partners Inc. raised its holdings in shares of Bristol-Myers Squibb by 0.7% in the 2nd quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock valued at $120,000 after acquiring an additional 15 shares in the last quarter. Jackson Grant Investment Advisers Inc. raised its holdings in shares of Bristol-Myers Squibb by 0.4% in the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 3,905 shares of the biopharmaceutical company’s stock valued at $218,000 after acquiring an additional 15 shares in the last quarter. Chilton Investment Co. LLC raised its holdings in shares of Bristol-Myers Squibb by 0.5% in the 2nd quarter. Chilton Investment Co. LLC now owns 5,283 shares of the biopharmaceutical company’s stock valued at $294,000 after acquiring an additional 26 shares in the last quarter. Keel Point LLC raised its holdings in shares of Bristol-Myers Squibb by 0.6% in the 2nd quarter. Keel Point LLC now owns 6,325 shares of the biopharmaceutical company’s stock valued at $352,000 after acquiring an additional 39 shares in the last quarter. Finally, Hudock Capital Group LLC raised its holdings in shares of Bristol-Myers Squibb by 0.4% during the 2nd quarter. Hudock Capital Group LLC now owns 11,775 shares of the biopharmaceutical company’s stock valued at $656,000 after buying an additional 49 shares in the last quarter. 69.82% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: “Analysts Anticipate Bristol-Myers Squibb Co (BMY) to Post $0.87 Earnings Per Share” was first posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The correct version of this news story can be viewed at https://www.thelincolnianonline.com/2018/02/23/analysts-anticipate-bristol-myers-squibb-co-bmy-to-post-0-87-earnings-per-share.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.